- Home
- UFCS vs EYPT Comparison
UFCS vs EYPT Comparison
Compare UFCS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- EYPT
- Stock Information
- Founded
- UFCS 1946
- EYPT 1987
- Country
- UFCS United States
- EYPT United States
- Employees
- UFCS N/A
- EYPT N/A
- Industry
- UFCS Property-Casualty Insurers
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- UFCS Finance
- EYPT Industrials
- Exchange
- UFCS Nasdaq
- EYPT Nasdaq
- Market Cap
- UFCS 642.7M
- EYPT 594.5M
- IPO Year
- UFCS N/A
- EYPT 2005
- Fundamental
- Price
- UFCS $25.87
- EYPT $7.43
- Analyst Decision
- UFCS Hold
- EYPT Strong Buy
- Analyst Count
- UFCS 1
- EYPT 8
- Target Price
- UFCS $26.00
- EYPT $25.71
- AVG Volume (30 Days)
- UFCS 133.0K
- EYPT 890.4K
- Earning Date
- UFCS 02-11-2025
- EYPT 03-06-2025
- Dividend Yield
- UFCS 2.52%
- EYPT N/A
- EPS Growth
- UFCS N/A
- EYPT N/A
- EPS
- UFCS 1.94
- EYPT N/A
- Revenue
- UFCS $1,207,451,000.00
- EYPT $45,713,000.00
- Revenue This Year
- UFCS N/A
- EYPT N/A
- Revenue Next Year
- UFCS $11.31
- EYPT N/A
- P/E Ratio
- UFCS $13.17
- EYPT N/A
- Revenue Growth
- UFCS 10.95
- EYPT 7.50
- 52 Week Low
- UFCS $18.04
- EYPT $6.90
- 52 Week High
- UFCS $31.70
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- UFCS 32.04
- EYPT 43.70
- Support Level
- UFCS $25.20
- EYPT $7.54
- Resistance Level
- UFCS $29.01
- EYPT $9.50
- Average True Range (ATR)
- UFCS 0.68
- EYPT 0.59
- MACD
- UFCS -0.50
- EYPT 0.10
- Stochastic Oscillator
- UFCS 17.49
- EYPT 27.03
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.